Abstract:In vivo microdialysis was used to examine baseline and KCl‐evoked dopamine alterations in the striatum in the alpha‐synuclein (α‐syn) preformed fibril (PFF) model. PFF injection resulted in α‐syn inclusion accumulation and significant loss of nigral tyrosine hydroxylase (TH) immunoreactive neurons and striatal TH and dopamine transporter expression. Both basal and evoked striatal DA, as well as decreased motor performance, were significantly impacted 8 months following PFF injection. However, deficits in striatal dopaminergic transmission emerged much later than the loss of nigrostriatal circuitry. Our results demonstrate that dopaminergic transmission is relatively maintained for long intervals following PFF injection. Parkinson's disease (PD) is characterized by the accumulation of misfolded alpha‐synuclein (α‐syn) protein, forming intraneuronal Lewy body (LB) inclusions. The α‐syn preformed fibril (PFF) model of PD recapitulates α‐syn aggregation, progressive nigrostriatal degeneration and motor dysfunction; however, little is known about the time course of PFF‐induced alterations in basal and evoked dopamine (DA). In vivo microdialysis is well suited for identifying small changes in neurotransmitter levels over extended periods. In the present study, adult male Fischer 344 rats received unilateral, intrastriatal injections of either α‐syn PFFs or phosphate‐buffered saline (PBS). At 4 or 8 months post‐injection (p.i.), animals underwent in vivo microdialysis to evaluate basal extracellular striatal DA and metabolite levels, local KCl‐evoked striatal DA release and the effects of systemic levodopa (l‐DOPA). Post‐mortem analysis demonstrated equivalent PFF‐induced reductions in tyrosine hydroxylase (TH) immunoreactive nigral neurons (~50%) and striatal TH (~20%) at both time points. Compared with reduction in striatal TH, reduction in striatal dopamine transporter (DAT) was more pronounced and progressed between the 4‐ and 8‐month p.i. intervals (36% ➔ 46%). Significant PFF‐induced deficits in basal and evoked striatal DA, as well as deficits in motor performance, were not observed until 8 months p.i. Responses to l‐DOPA did not differ regardless of PBS or PFF treatment. These results suggest that basal and evoked striatal DA are maintained for several months following PFF injection, with loss of both associated with motor dysfunction. Our studies provide insight into the time course and magnitude of PFF‐induced extracellular dopaminergic deficits in the striatum.

Intranasal administration of -synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of <i>Macaca fascicularis</i>

Intranasal administration of α-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis

Genetic Impacts on Nigral Iron Deposition in Parkinson's Disease: A Preliminary Quantitative Susceptibility Mapping Study.

Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping.

Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson's Disease on Brain Networks

Antioxidant Nanoparticles for Concerted Inhibition of α-Synuclein Fibrillization, and Attenuation of Microglial Intracellular Aggregation and Activation

Iron-related Nigral Degeneration Influences Functional Topology Mediated by Striatal Dysfunction in Parkinson's Disease.

Spatiotemporal Neurodegeneration of the Substantia Nigra and Its Connecting Cortex and Subcortex in Parkinson's Disease.

Iron deposition in substantia nigra: abnormal iron metabolism, neuroinflammatory mechanism and clinical relevance

The Synergistic Effect Study of Lipopolysaccharide (LPS) and A53T-α-Synuclein: Intranasal LPS Exposure on the A53T-α-Synuclein Transgenic Mouse Model of Parkinson's Disease

IL‐1β/IL‐1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha‐Synuclein pathology in the olfactory bulb, substantia nigra and striatum

IL-1/IL-1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha-synuclein pathology in the olfactory bulb, substantia nigra and striatum

Iron Reduces the Propagation of Pathological -Synuclein an Editorial Highlight for "brain Iron Enrichment Attenuates -Synuclein Spreading after Injection of Preformed Fibrils"

Iron Deposition Leads to Neuronal Α-Synuclein Pathology by Inducing Autophagy Dysfunction.

Iron Reduces the Propagation of Pathological Α‐synuclein

An altered blood-brain barrier contributes to brain iron accumulation and neuroinflammation in the 6-OHDA rat model of Parkinson's disease

Iron Chelation Nanoparticles with Delayed Saturation As an Effective Therapy for Parkinson Disease.

Deficits in basal and evoked striatal dopamine release following alpha‐synuclein preformed fibril injection: An in vivo microdialysis study

Cell senescence induced by toxic interaction between α-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson's disease

The Spreading and Effects of Human Recombinant {alpha}-Synuclein Preformed Fibrils in the Cerebrospinal Fluid of Mice

Microglial inhibition alleviates alpha-synuclein propagation and neurodegeneration in Parkinson’s disease mouse model